Tag: Intellia Therapeutics

Shares of genome-editing company Intellia Therapeutics closed the trading week in negative territory, continuing a period of pronounced weakness. The ...

Shares of Intellia Therapeutics are experiencing significant downward pressure, with the stock price declining 3.80% to $8.10 as investor sentiment ...

A significant shift in analyst sentiment is casting a shadow over Intellia Therapeutics, sending its stock downward and prompting investors ...

A severe clinical setback has struck Intellia Therapeutics, sending its stock value tumbling after the U.S. Food and Drug Administration ...

A dramatic reassessment is underway for Intellia Therapeutics, sending shockwaves through the biotech investment community. Market research firm Morningstar has ...

While market sentiment remains divided, a significant move by a major investment firm suggests growing institutional confidence in gene-editing specialist ...

A patient death in a key study has triggered a severe downturn for Intellia Therapeutics, with the gene-editing company's stock ...

Intellia Therapeutics, a prominent player in the gene-editing sector, is confronting a severe crisis after a fatality occurred in a ...

Intellia Therapeutics captured significant market attention on November 16 when the biotechnology firm unveiled groundbreaking clinical trial data for its ...

Intellia Therapeutics is confronting one of its most severe market downturns following a cascade of negative developments that have severely ...